Reference
·Supporting source
Thailand pharma facilities with EU GMP cross-certification (2024)
~12 facilities
Approximately 12 Thailand-licensed pharmaceutical manufacturing facilities hold active EU GMP cross-certification as of 2024 per Thai FDA tracking and EudraGMDP database extracts, enabling direct export of finished dosage forms to EU member states under national competent authority inspection equivalence. Facilities span Mega Lifesciences, Siam Bioscience, Olic Thailand, Olic Mae Ramphueng plant, Bangkok Drug, and select Big Pharma multinational satellite plants. EU GMP-listed facilities anchor Thailand's higher-margin pharma export book to Europe, the Middle East, and Africa, complementing the broader PIC/S-recognised baseline.
Figure in context
Approximately 12 Thailand-licensed pharmaceutical manufacturing facilities hold active EU GMP cross-certification as of 2024 per Thai FDA tracking and EudraGMDP database extracts, enabling direct export of finished dosage forms to EU member states under national competent authority inspection equivalence. Facilities span Mega Lifesciences, Siam Bioscience, Olic Thailand, Olic Mae Ramphueng plant, Bangkok Drug, and select Big Pharma multinational satellite plants. EU GMP-listed facilities anchor Thailand's higher-margin pharma export book to Europe, the Middle East, and Africa, complementing the broader PIC/S-recognised baseline.
Approximately 12 Thailand-licensed pharmaceutical manufacturing facilities hold active EU GMP cross-certification as of 2024 per Thai FDA tracking and EudraGMDP database extracts, enabling direct export of finished dosage forms to EU member states under national competent authority inspection equivalence. Facilities span Mega Lifesciences, Siam Bioscience, Olic Thailand, Olic Mae Ramphueng plant, Bangkok Drug, and select Big Pharma multinational satellite plants. EU GMP-listed facilities anchor Thailand's higher-margin pharma export book to Europe, the Middle East, and Africa, complementing the broader PIC/S-recognised baseline.
Time scope
2024
Source basis
Supporting source
Interpretation notes
What this tells you
Approximately 12 Thailand-licensed pharmaceutical manufacturing facilities hold active EU GMP cross-certification as of 2024 per Thai FDA tracking and EudraGMDP database extracts, enabling direct export of finished dosage forms to EU member states under national competent authority inspection equivalence. Facilities span Mega Lifesciences, Siam Bioscience, Olic Thailand, Olic Mae Ramphueng plant, Bangkok Drug, and select Big Pharma multinational satellite plants. EU GMP-listed facilities anchor Thailand's higher-margin pharma export book to Europe, the Middle East, and Africa, complementing the broader PIC/S-recognised baseline.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical manufacturing factory-gate revenue (2020-2024)
Thai FDA, Pharmaceutical Research and Manufacturers Association of Thailand, Krungsri Research, Bangkok Post pharma coverage
Thailand pharmaceutical generic vs branded mix (2024)
PReMA, IQVIA Thailand, Thai FDA, Government Pharmaceutical Organization
Thailand pharmaceutical manufacturer revenue share (2024)
PReMA, Thai FDA, GPO annual report, Mega Lifesciences, industry estimates
BOI Future Medicine approved projects (2020-2024)
Thailand Board of Investment, BOI Future Medicine sector briefing, NESDC
Thailand FDA GMP-certified pharmaceutical facility count (2024)
Thai FDA Drug Control Division, PIC/S accession documentation, PReMA, industry estimates
Siam Bioscience vaccine output capacity (2024)
Siam Bioscience disclosures, PReMA, Bangkok Post pharma coverage, WHO prequalification listing
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.